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Abstract
Since the mid-1990s, the multiple myeloma (MM) treatment landscape has evolved considerably, 
which has led to improved patient outcomes and prolonged survival. In addition to discovering 
new, targeted agents or treatment regimens, the identification and validation of biomarkers has the 
potential to further improve patient outcomes. The International Staging System (ISS) relies on a 
number of biochemical parameters to stratify patients into risk categories. Other biologically 
relevant markers that are indicative of inherited genetic variation (e.g., single nucleotide 
polymorphisms) or tumor acquired genetic events (e.g., chromosomal translocations or mutations) 
have been studied for their prognostic potential. In patients with high-risk (HR) cytogenetics, 
plasma cells (PCs) undergo genetic shifts over time, which may partially explain why HR patients 
relapse and are so difficult to treat. Although novel agents have improved treatment outcomes, 
identification of markers that will enable clinicians to determine which treatment is most 
appropriate for HR patients following initial diagnosis represents an exciting frontier in the clinical 
management of MM. Biomarkers based on quantitating PCs or factors that are secreted from them 
(e.g., serum free light chain) may also help to risk-stratify patients with asymptomatic MM. 
Eventually, identification of novel biomarkers may lead to the creation of personalized treatment 
regimens that are optimized to target clonal PCs that express a specific oncogenomic profile. 
Although the future is exciting, validation will be necessary before these biologic and molecular 
beacons can inform decision-making processes in a routine clinical setting.
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Introduction
Multiple myeloma (MM) is a hematologic disease that is characterized by the proliferation 
of abnormal bone marrow plasma cells (BMPCs) and immunoglobulin (Ig) or light chain 
overproduction, with evidence of end-organ damage. Prior to 1997, the median survival of 
patients with newly diagnosed MM was approximately 2.5 years (1). From 1997 to 2006, the 
use of high-dose anti-MM therapy, stem cell transplantation, and novel agents increased 
median overall survival (OS) to nearly 4 years, a 50% improvement (1). In some patients 
who are currently receiving such agents, improved relapse-free survival has increased to > 
10 years (2), raising the potential for long term disease control and care.
Although the MM treatment landscape has improved since the mid-1990s, the intraclonal 
heterogeneity of malignant plasma cells (PCs), the interaction of PCs with host factors, and 
the bone marrow (BM) microenvironment contribute to disease progression and the 
molecular evolution of the disease according to “Darwinian” principles (3, 4). Taken 
together, these factors contribute to the generation of treatment-resistant PCs, which 
ultimately leads to relapsed and refractory myeloma (RRMM), the disease stage that is 
frequently used for drug development. However, as the nature of this disease stage continues 
to change as a consequence of patients receiving multiple lines of therapy, it is essential that 
we develop novel approaches to drug development.
If patients are to overcome treatment resistance, one approach that may improve clinical 
outcomes is to select treatments that are well matched to a patient's molecularly defined 
disease subtype (5). Another promising approach is to identify new biomarkers and tools 
that can identify onset or worsening of disease. According to the National Cancer Institute 
(NCI), a biomarker is a molecule that is found in blood and other body fluids or tissues that 
can serve as an indicator for a normal or abnormal process, condition, or disease (6). Herein, 
we will review biomarkers that have been used in MM that meet the NCI's definition of a 
biomarker (e.g., monoclonal [M] protein); we will also discuss molecular markers and tools 
that have the potential to dramatically alter how clinicians diagnose, stage, and treat patients 
with MM or asymptomatic “early” MM.
The emergence of clinical biomarkers in multiple myeloma
In the 1960s, MM researchers began to identify biomarkers that were independent predictors 
of survival, including hemoglobin, serum calcium, serum creatinine, and bone lesion 
severity (7, 8). In 1975, Durie and Salmon introduced a staging system that used monoclonal 
(M) protein, hemoglobin, calcium, and the number of bone lesions to predict MM cell tumor 
burden (9). In the 1980s, serum β2-microglobulin (β2M) was found to be a simple, yet 
reliable prognostic marker for disease staging; serum β2M also enabled clinicians to predict 
a patient's likelihood of survival (10, 11). Subsequently, albumin (12), C-reactive protein 
(13), and BMPC proliferation indices (14, 15) were found to be reliable prognostic factors, 
but didn't come into general use. In 2005, an international consortium of researchers used 
serum β2M and serum albumin to create the International Staging System (ISS), which 
enabled clinicians to stage patients and predict their long-term prognosis (16). This has been 
further refined by combining FISH data with ISS staging (17, 18).
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Other types of biomarkers (e.g., serum free light chain [sFLC] ratio and cytogenetic 
markers) are also beginning to provide prognostic information in MM and patients with 
asymptomatic disease (18-20). There have been significant developments in the diagnostic 
platforms that are available to assess the molecular features of MM that provide extensive 
novel information as well as new diagnostic tests. The current emphasis is on using multi-
parallel genome wide approaches, which yield huge amounts of data and offer the advantage 
of being able to multiplex genomes from many patients in a single run, which can reduce the 
cost per test. However, these technologies also raise significant issues with regard to the 
generation of complex datasets and how they can be reliably analyzed. These technologies 
will need to be robust and applicable if they are to be widely used in a routine setting. It is 
also appropriate to ask whether we should take a genome wide approach to biomarker 
development or whether we should focus on a smaller number of “MM relevant” markers 
that can be analyzed using simpler and potentially more robust techniques.
Cytogenetic biomarkers in multiple myeloma
Changes at the DNA level determine how a cancer cell behaves. If we can understand these 
molecular events, we should be able to predict the behavior of cancer. Chromosomal 
translocations are primary genetic events that occur early in the disease and are seen in 
roughly 50% of MM patients. As a consequence of the translocation events, there is 
overexpression of partner genes, leading to abnormal clonal PC behavior and differing 
clinical outcomes (17, 21-27). For example, respective four-year progression-free survival 
(PFS) and OS rates for patients with the t(4;14) have been estimated to be 11% and 35% 
versus PFS and OS rates of 32% and 60% for patients without the t(4;14) (18).
Other chromosomal translocations have been investigated for their prognostic potential. The 
t(14;16) is present in < 5% of patients with newly diagnosed MM and defines a group of 
patients who often have poor survival (17, 18, 28, 29). Although the t(14;16) is relatively 
rare, the MAF gene is overexpressed in up to 30% of MM patients, defining a greater 
number of patients with a unifying biological feature (4). The t(11;14) is observed in 
approximately 20% of patients and is associated with a favorable prognosis, higher rates of 
CD20 expression, lymphoplasmacytic morphology, hyposecretory disease, λ-light chain 
usage, and nuclear cyclin D1 (CCND1) expression and dysregulation (18, 21, 23, 30-32).
Hyperdiploidy of the odd-numbered chromosomes is the other major primary genetic event 
in MM that defines the other 50% of MM cases (Table 1) (4, 33-36). Although the exact 
cause of hyperdiploidy is unknown, it seems to define a group of patients with a more 
favorable prognosis (37). In addition to chromosomal translocations and hyperdiploidy, 
inherited genetic variation is an important factor in the etiology of MM. Molecular 
epidemiology techniques have shown that MM is associated with SNPs at the chromosomal 
regions 2p, 3p, 6p, 7p, 17p and 11q (4, 34, 35). However, at this point no prognostic value 
has been seen in association with these variables. Inherited variation can also affect response 
to chemotherapy and the side effect profile of a drug. To date, very few studies have been 
carried out to test this hypothesis, and they have not as yet defined relevant markers that can 
be used in this way in MM (38).
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Secondary genetic events, which are important in disease progression, also affect various 
molecular pathways and contribute to the biological heterogeneity of PCs (Table 2). In this 
context, prognostically important copy number abnormalities (including gains or deletions 
of whole chromosomes or interstitial copy number gains) have been identified using SNP 
mapping arrays (4, 18, 33, 39). Clinically relevant regions that have been identified using 
this approach include 1q+, 1p32-, 1p11- and 17p-. The International Myeloma Working 
Group (IMWG) has recommended assessing these specific cytogenetic lesions at disease 
presentation, as they may have prognostic value that is clinically relevant. The study of copy 
number change has also improved our understanding of the biology of MM, leading to the 
identification of 16q, a WW domain-containing oxidoreductase gene (WWOX), CYLD (a 
negative regulator of the NF-κΒ pathway), 11q- (BIRC2 and BIRC3), and 14q (TRAF3) as 
being relevant recurrent events (40, 41). These findings reinforce the importance of using 
therapeutic approaches to target the NF-κΒ pathway.
The use of massively parallel sequencing has identified hundreds of mutations in MM (42, 
43); however, no consistently mutated gene has been identified that characterizes all 
occurrences of the disease. Nevertheless, these studies are in their infancy; the prognostic 
relevance of the multitude of exonic mutations that have been identified has yet to be 
determined. While potentially useful, one challenge with interpreting sequencing data is 
defining which mutations are so called “driver variants” that are important to disease 
pathogenesis rather than being “passenger variants” which are present by virtue of being 
carried forward by their association with other pathogenetically important genes. Driver 
mutations identified by this approach may be important therapeutic targets that could be 
used to design targeted treatment approaches.
Biomarker development
If we are to use tumor acquired genetic variants as biomarkers, it is important to consider 
their specificity and sensitivity for identifying the clinical outcome of interest (e.g., PFS, OS, 
or side effects). There is now considerable data on the use of “FISH detected” cytogenetic 
markers to predict clinical outcomes. What is clear from these data is that no single marker 
offers either good sensitivity or specificity for the prediction of either PFS or OS. If we are 
to alter treatment following use of a FISH-based cytogenetic approach, we will need to use a 
comprehensive panel of markers to define risk based on both the number and nature of the 
adverse markers detected. iFISH combined with the ISS is useful, but general applicability 
and issues with sensitivity and specificity remain. Some of these challenges can be overcome 
by counting the number of abnormal lesions that are present and using the number present as 
a way of defining risk. This approach combined with the use of a comprehensive panel of 
markers, including the adverse translocations t(4;14) and MAF together with the adverse 
copy number variables 1q+, 1p- and 17p- can provide very complete clinical data.
Global gene expression profiling (GEP) and prognostic signatures provide an alternative 
approach to FISH (44). Although GEP and prognostic signatures offer greater specificity in 
patients who are identified as having a poor prognosis, they lack biological relevance and 
remain difficult to apply in a routine clinical setting. However, GEP does provide a massive 
amount of data and can define the groups identified in the TC classification as well as being 
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able to detect prognostic signatures. At this time, GEP cannot usefully identify the adverse 
groups defined by 1q+ and 17p-; these 2 subgroups with a poor prognosis still need to be 
detected by iFISH. The eventual clinical application and regular use of such biomarkers 
depends upon their clinical applicability together with the availability of effective treatments 
for use in specific patient subgroups.
The technology used to detect a cytogenetic biomarker is also of critical importance. 
Historically, metaphase cytogenetic analysis was used, but this only gave results in 18% of 
patients and was therefore not widely adopted. Although FISH on CD138-selected PCs is 
applicable and gives results in nearly 100% of patients if adequate numbers of tumor cells 
are obtained, this method is slow and expensive and up to now has lacked sensitivity and 
specificity. For predicting clinical outcomes, new genome wide technologies are useful, yet 
their design and application are still in their infancy. Alternative strategies that may be more 
applicable for detecting copy number changes include multiplex ligation-dependent probe 
amplification (MLPA), which can detect the clinically relevant MM-associated copy number 
variants at a fraction of the cost of FISH. MLPA can also deliver results in a more timely 
fashion while GEP can define risk status based on poor prognosis signatures. An alternative 
expression-based approach is to design real-time quantitative polymerase chain reaction 
(RQ-PCR) assays that can identify TC classification groups and prognostically relevant 
genes (45). If these assays are combined with MLPA copy number variant assays, this 
approach can provide all of the relevant prognostic variants in a set of tests that are readily 
applicable.
MicroRNAs (miRNAs), which are more stable than conventional RNA, can be detected in 
serum as well as in malignant PCs (46). In this context, most work on MM biomarkers has 
focused on BMPCs; little work has been done on circulating PCs or serum DNA or RNA. 
These areas offer considerable opportunities for future development (3, 47). Additionally, 
important epigenetic events—including global DNA hypomethylation and gene-specific 
DNA hypermethylation—are beginning to provide insights into the etiology of disease 
progression and could lead to the identification of clinically useful biomarkers (4, 48, 49).
The development of clinically relevant biomarkers is now being shaped by the regulatory 
framework for such testing. The Clinical Laboratory Improvement Amendments (CLIA) 
approach suggests that the development of biomarkers needs to be done in defined 
laboratories that work according to relevant standard operating procedures. This implies that 
biomarkers all need to be developed in the context of clinical trials where data are collected 
according to the principles of good clinical practice (GCP) and the biomarkers are 
determined in a laboratory working to CLIA standards. In the absence of such an approach, 
biomarkers cannot be adopted into clinical practice.
Risk-stratified treatment of MM
The identification of patient-specific cytogenetic abnormalities and patients' gene mutation 
status may be particularly useful in helping to direct treatment in patients with MM who 
possess a specific oncogenomic profile (5). It is now possible to define LR and HR disease 
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subsets using GEP and FISH (50). GEP is useful in defining the molecular subtypes of MM 
as well as being able to define signatures of HR disease (50-53).
Based on data analyses from platforms that are derived from completed studies, we are 
making progress toward improving the outcomes of patients with standard-risk (SR) disease. 
Nevertheless, we have made little progress toward treating or managing patients with HR 
disease. These observations argue in favor of moving toward the design of clinical trials that 
specifically develop treatments for HR disease. However, before we can design such studies, 
the biomarkers for robustly identifying these risk groups need to be validated in order for us 
to screen an adequate number of patients in the molecular subgroup of interest. This clinical 
trial approach will require us to fully embrace modern genomic technologies that are 
applicable in routine diagnostic facilities.
“Clinical response” as a biomarker
Changes in BMPCs, paraprotein, and light chains form the basis of assessing patient 
response to therapy and could be used as an alternative treatment end point. The standard 
approach to using these data is with the criteria laid out in the IMWG response criteria (54). 
The achievement of complete response (CR) is an important end point when assessing new 
therapies (Table 3); it seems likely that the deeper the level of response, the better the 
clinical outcome will be. Indeed, the achievement of a CR with no detectable disease is the 
essential prerequisite for a cure. Thus, the definition of stringent CR and the criteria defining 
this state are of some importance. The IMWG defines stringent complete response (sCR) 
similarly to CR, but MM patients must also have a normal FLC ratio with no evidence of 
clonal BMPCs (assessed using immunohistochemistry or 2- to 4- color flow cytometry) (54). 
There is a consensus that is beginning to emerge on the most appropriate panel of antibodies 
and the strategy for detecting malignant PCs, with considerable enthusiasm being directed 
toward their use as a definitive clinical endpoint. Flow cytometry has considerable merit for 
monitoring residual disease because it offers sensitivity and does not require one to design 
patient/clono-specific approaches; it can also be performed in most hemato-oncology 
diagnostic laboratories.
A recent survey that included 30 major medical institutions in the US found that the 
application of multicolor flow cytometry for minimal residual disease (MRD) in MM varies 
greatly (55). Indeed, the definition of abnormal PCs differed substantially between 
institutions, with some relying on CD19 and CD45 negativity with or without CD56 
positivity to determine the extent of MRD despite previous studies showing that normal PC 
subpopulations can be negative for CD19 and CD45 or CD56 positive (56, 57). More 
specific antigens such as CD27, CD81 and CD117 were used by less than half of the 
institutions. Even more importantly, there is considerable variation in the number of BMPCs 
analyzed (i.e., events) and the number of abnormal PCs that are needed to determine the 
presence of MRD, which affects the maximum possible sensitivity of the assay. In this 
survey, it was found that the maximum detection sensitivity ranged from 0.0005% to 0.02%, 
a 100-fold difference in sensitivity. Such data copies the establishment of standardized 
approaches and external quality control programs. It is important to contrast this with 
multiparameter flow cytometry with the application of clono-specific PCR for the same 
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purpose. In most settings, the clono-specific PCR offers greater sensitivity, but this 
technique has been hampered by the necessity to develop clono-specific probes, which has 
made its general application cumbersome and expensive. This situation is now changing 
with the advent of massively parallel sequencing approaches, which utilize probes that can 
be used to tile entire IgH regions (43). This approach is sensitive, high throughput, and 
universally applicable.
Predictive biomarkers
In recent years, it has become evident that patients with the t(4;14) have more favorable 
outcomes when they are treated with proteasome inhibitors. A group at the Mayo Clinic 
recently discussed the concept of “risk-adapted therapy” (5) whereby patients with high-risk 
disease (i.e., patients with the t(14;16), t(14;20), and/or del17p) may be better candidates for 
triplet combination therapy (e.g., bortezomib-lenalidomide-dexamethasone) compared to 
patients with intermediate- or standard-risk disease. Although triplet combinations may have 
a less favorable side effect profile relative to “single-agent” therapies, triplet combination 
regimens are more appropriate for patients with high-risk disease because median overall 
survival in that cohort is only 3 years compared to 4-5 years and 8-10 years for patients with 
intermediate-risk and standard-risk disease, respectively. In the absence of using cytogenetic 
markers to risk-stratify transplant-eligible and transplant-ineligible patients, it would be 
difficult to determine which treatment regimen is most appropriate for patients with multiple 
myeloma.
Nevertheless, the t(4;14) cannot be considered to be a true prognostic biomarker because 
many patients who lack this translocation also respond and have good clinical outcomes 
following proteasome inhibitor therapy. Moving forward, information from genome wide 
sequencing studies is leading to the identification of frequent pathogenetically important 
mutations in MM, including those involved in the ERK signal transduction pathway. These 
biomarkers include NRAS, KRAS, and BRAF (4). In recent years, BRAF-V600E has 
emerged as one of the most promising ERK mutations that can be targeted, validating the 
concept of targeted treatment. For example, one MM patient with extramedullary disease 
and the BRAF-V600E mutation responded well to low doses of vemurafenib, a mutation-
specific BRAF inhibitor (58), making it a true predictive biomarker in the absence of which 
a response was not observed.
One potential issue with use of targeted therapy is the presence of intraclonal heterogeneity 
(ICH) relating to subclonal variability. ICH is the essential substrate for clonal evolution 
according to the principles of Darwinian evolution (4). In recent years, three patterns of 
clonal evolution have been identified: relapse can be genetically stable; it can linearly evolve 
with several new genetic variants at relapse; or it can come from a clone that wasn't present 
at the time of diagnosis (59). Paired sample analysis of 28 MM patients revealed that 
patients with SR cytogenetics typically have PC clones that are genetically stable (59). In 
contrast, patients with HR cytogenetics have PC clones that undergo many more genetic 
modifications over time.
The presence of ICH has important implications for the development of biomarkers. 
Although it was once acceptable to determine whether a molecular target was present, it is 
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now essential to obtain an idea of the size of the sub-clone carrying the target. The size of 
the clone has important therapeutic implications for targeted treatment because completely 
eradicating a clone present only 5% of the time would have little importance clinically, 
whereas in a clone present 90% of the time, there would be a significant clinical response.
The presence of ICH also has an effect on the assessment and treatment of relapse. 
Traditionally, clinical data were used to define prognosis, response to therapy, duration of 
prior response, rate of relapse, the presence of extramedullary or blastic disease, 
performance status, and the toxicity of prior treatment. In the era of molecular medicine, 
cytogenetics, focal lesions, tidal clone status (i.e., same clone, new mutant, or prior clone), 
GEP signature, and methylation status are beginning to provide clinicians with more 
information about the clinical behavior of the disease at relapse.
Biomarkers in MGUS and smoldering multiple myeloma
In the 1970s, Kyle and Greipp began to use the phrases “monoclonal gammopathy of 
undetermined significance (MGUS)” and “smoldering multiple myeloma (SMM)” to 
describe premalignant PC disorders that are not associated with end organ damage or 
treatment (60, 61). Currently, asymptomatic MM is an active area of biomarker research 
where the challenge is to predict those patients who are at HR of disease progression for 
whom treatment intervention is essential to prevent the emergence of significant end organ 
damage. The use of many of the molecular markers described above is difficult because the 
molecular features of MM that require treatment are often present in patients with 
asymptomatic disease (62, 63), meaning that alternative approaches to predict risk status are 
required.
In 2003, the IMWG used laboratory and clinical markers (e.g., serum and urine M protein, 
clonal BMPCs, and sFLC) to define patients with asymptomatic MM where treatment was 
not indicated (64). The sFLC ratio is one of the most promising biomarkers in asymptomatic 
MM; it has been used as a prognostic indicator in patients with MGUS (65), SMM (66-68), 
and newly diagnosed MM (69), but it is not without controversy. The Spanish Programa 
Español de Tratamientos en Hematologίa (PETHEMA) and Mayo Clinic groups both used 
sFLC ratios, circulating PCs, and PC proliferation rates to create two models that classify 
asymptomatic patients as being at low-, intermediate-, or HR of disease progression (66, 70). 
A group at the NCI used the Spanish PETHEMA Model (70) and the Mayo Clinic Model 
(66) to categorize 77 patients with SMM as being at low-risk (LR), intermediate-risk, or HR 
of developing active MM (71). In the NCI's study, concordance between the PETHEMA and 
Mayo Clinic Models was low (28.6%); there was also significant discordance between how 
each model classified patients' risk status. Thus, although characterization of PC 
immunophenotype and measuring sFLC ratios both have prognostic potential, they lack 
specificity and do not have enough positive predictive value to be useful in determining 
when treatment should be initiated in patients with asymptomatic disease.
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Imaging tools for “early” myeloma
Given that nearly all patients with symptomatic MM develop osteolytic lesions, clinicians 
use BM aspirates and trephine samples to monitor bone morphology throughout the course 
of disease progression. Although these tools are useful, there can be variability in the 
distribution of BMPCs throughout the body, increasing the likelihood of heterogeneous 
sample recovery and sampling error, particularly in patients with asymptomatic disease. 
Given the importance of understanding the underlying biology of bone in MM, clinicians 
use x-rays to complete skeletal surveys, a technique that is currently the gold standard for 
evaluating severity of bone disease. Despite the utility of skeletal surveys, magnetic 
resonance imaging (MRI), computed tomography (CT), and positron emission tomography 
(PET)/CT scanning are becoming increasingly important tools for assessment of disease 
severity. MRI is a useful noninvasive technique for imaging the spine, soft tissue, and 
infiltration of BMPCs and is particularly useful for patients with SMM because it can detect 
diffuse lesions, the presence of which is an adverse prognostic factor for PFS (72). In 
addition, detection of seven or more focal lesions with MRI is considered to be an adverse 
prognostic factor in patients with MM (73). If MRI is unavailable, CT may be helpful for 
assessing the extent of damage to the spine or soft tissues. Nevertheless, its use should be 
limited because CT can expose patients to nearly three times more radiation than 
conventional MRI. Lastly, fusion of CT and fluorodeoxyglucose (FDG) PET images can be 
very useful for evaluation of patients with symptomatic disease and has the potential to be 
useful in patients with MGUS or SMM (74). In the future, functional imaging techniques 
that are used in combination with biomarker data are likely to contribute to the management 
of patients with “early” MM and the development of novel MRD assays.
Target Modulation
Cytotoxic chemotherapy, immunomodulatory agents, and proteasome inhibitors have been 
highly effective and universally applicable in MM. Going forward, the next generation of 
targeted treatments will depend not only on the presence of a target, but also on their ability 
to modulate their target. This will be especially important during the early phases of clinical 
development of targeted treatments, where target modulation should be considered to be an 
important endpoint. In MM, it is, perhaps, not optimal to use circulating lymphocytes as 
targets to assess target modulation because of differences in cellular biology and tissue 
penetration. Consequently, access to and characterization of BMPCs is important and can be 
achieved using immunohistochemistry on BM trephines or flow cytometry on aspirate 
samples. Examples include the assessment of antiapoptotic proteins to predict a patient's 
response to agents that target these pathways, the demonstration of down-regulation of 
pERK, or evidence of changes in histone methylation states following evaluation of MMSET 
inhibitors.
Summary and Future Directions
Over the past 40 years, biomarkers such as M-protein and serum β2M have contributed 
innumerable insights into our present understanding of MM. Today, many cytogenetic 
markers are beginning to provide information about the severity of disease; these markers 
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are also beginning to inform clinicians regarding which anti-MM treatment regimen is most 
appropriate for a particular patient. It is clear that rapid technological advances are changing 
the way biomarkers are perceived as well as their clinical relevance (Figure 1). In the near 
future, diagnostic tests based on massively parallel sequencing approaches will enable 
detection of recurrent molecular abnormalities as well as actionable mutations that are rarely 
observed but which could utilize treatments that are used in other disease settings. Massively 
parallel sequencing approaches will also enable clinicians to monitor disease longitudinally, 
which may provide opportunities for early intervention before clonal PC expansion and 
disease complexity render existing treatments ineffective. Finally, combining functional 
imaging techniques with assays that utilize biomarkers has the potential to change clinical 
practice in patients with “early” myeloma and patients with symptomatic disease.
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Figure 1. Technological advances in detecting biomarkers in multiple myeloma
FISH, fluorescence in situ hybridization; miRNA, micro RNA; TC, transporter 
classification.
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Table 1
Inherited Variation and Primary Genetic Events in Multiple Myeloma
Inherited Variation
Single-nucleotide polymorphisms (SNPs)
Chromosome Gene(s) Primary tool(s) Reference(s)
2p23.3 DTNB and DNMT3A
GWAS (34, 35)3p22.1 ULK4 and TRAK1
7p15.3 DNAH11 and CDCA7L
Primary Genetic Events
IGH@ translocations
Translocation Gene(s) Primary tool(s) Reference(s)
t(4;14) at 4p16.3 FGFR3 and MMSET
Karyotype analysis (cytogenetics), FISH, GEP, GWAS, RT-PCR 
or sequencing
(25)
t(6;14) at 6p21 CCND3 (21, 23)
t(11;14)(p21;q11) CCND1 (21, 23, 27)
t(14;16)(q32;q23) MAF (24)
t(14;20)(q32;q12) MAFB (17, 26)
Hyperdiploidy (chromosomal trisomy)
Chromosome(s) Gene(s) Primary tool(s) Reference(s)
3, 5, 7, 9, 11, 15, 19, and 21 GEP and FISH (41)
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Table 2
Secondary Genetic Events in Multiple Myeloma
Secondary Genetic Events
Secondary translocations
Chromosome(s) Gene(s) Tool(s) Reference(s)
t(8;14) MYC FISH (75)
Gains
Chromosome Gene(s) Tool(s) Reference(s)
1q CKS1B and ANP32E
GEP (41)
12p LTBR
17q Comparative genomic hybridization (CGH) (76)
Deletions
Chromosome Gene(s) Tool(s) Reference(s)
1p CDKN2C, FAF1 and FAM46C
GEP, GM and FISH
(41, 77)
6q (41)
8p TRAIL-R1 and TRAIL-R2 (41, 78)
11q BIRC2 and BIRC3 (79, 80)
13 RB1 and DIS3 (41)
14q TRAF3 (79, 80)
16q CYLD and WWOX (40, 41)
17p TP53 (41, 81)
Epigenetic events
Global hypomethylation (MGUS to MM) and gene-specific 
hypermethylation (MM to PC leukemia)
Genome-wide methylation arrays (49)
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Table 3
Partial List of Response Criteria from The European Group for Blood and Marrow 
Transplantation (EBMT) and the International Myeloma Working Group (IMWG)
Parameter EBMT Response Criteria (82) IMWG Uniform Response Criteriaa (54)
sCR
• Not defined Patient meets all of the following criteria:
• CR as defined
• Normal free light chain ratio
• Absence of clonal PCs by immunohistochemistry 
or 2- to 4-color flow cytometry
CR
Presence of all of the following:
• Absence of M-protein in serum 
and urine, measured by 
immunofixation, maintained for 
≥6 weeks
• <5% bone marrow plasma cells
– If absence of M-protein is 
sustained for 6 weeks, it is 
not necessary to repeat the 
bone marrow exam except 
in patients with 
nonsecretory MM
• No increase in size or number of 
lytic bone lesions
• Disappearance of soft tissue 
plasmacytomas
Patient meets all of the following criteria:
• Negative immunofixation of serum and urine
• Disappearance of any soft tissue plasmacytomas
• ≤5% PCs in bone marrow
Immunophenotypic CR
• Not defined Patient meets all of the following criteria:
• sCR as defined
• Absence of phenotypically aberrant PCs (clonal) in 
bone marrow with a minimum of 1 million total 
BM cells analyzed by multiparametric flow 
cytometry (with >4 colors)
Molecular CR
• Not defined Patient meets all of the following criteria:
• CR as defined
• Negative allele-specific oligonucleotide 
polymerase chain reaction (sensitivity 10-5)
VGPR
• Not defined Patient meets one of the following criteria:
• Serum and urine M-component detectable by 
immunofixation but not on electrophoresis
• ≥90% reduction in serum M-component plus urine 
M-component <100 mg/24 h
PR
Patient meets all of the following criteria:
• ≥50% reduction of serum M-
protein for ≥6 weeks
• Reduction in 24-hour urinary 
light chain excretion either by 
≥90% or to <200 mg for ≥6 
weeks
Patient meets all of the following criteria:
• ≥50% reduction of serum M-protein and reduction 
in 24 h urinary M-protein by ≥90% or to <200 
mg/24 h
• If serum and urine M-protein can't be measured, a 
≥50% decrease in the difference between involved 
and uninvolved FLC levels is required in place of 
the M-protein criteria
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Parameter EBMT Response Criteria (82) IMWG Uniform Response Criteriaa (54)
• Nonsecretory MM only: ≥50% 
reduction of plasma cells in BM 
aspirate for ≥6 weeks
• ≥50% reduction in the size of soft 
tissue plasmacytomas
• No increase in size or number of 
lytic bone lesions
• If serum and urine M-protein can't be measured, 
and serum free light assay also can't be measured, 
≥50% reduction in plasma cells is required in place 
of M-protein, provided baseline bone marrow 
plasma cell percentage was ≥30%
• In addition to the above listed criteria, if present at 
baseline, a ≥50% reduction in the size of soft tissue 
plasmacytomas is also required
a
CR, sCR, VGPR, and PR require 2 consecutive assessments to be made at any time before beginning any new therapy. If radiographic studies 
were performed, these categories also require no known evidence of progressive or new bone lesions.
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